Details for Patent: 7,981,894

Title:	Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
Abstract:	The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbomyl-benzofuran-5-yl)-piperazine, crystaline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbomyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.
Inventor(s):	Bathe; Andreas (Darmstadt, DE), Helfert; Bernd (Ober-Ramstadt, DE), Neuenfeld; Steffen (Messel, DE), Kniel; Heike (Heppenheim, DE), Bartels; Matthias (Darmstadt, DE), Rudolph; Susanne (Dieburg, DE), Bottcher; Henning (Darmstadt, DE)
Assignee:	Merck Patentgesellschaft (Darmstadt, DE)
Filing Date:	Sep 25, 2009
Application Number:	12/566,835
Claims:	1. A compound which is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride monohydrate in crystalline modification V (Form V) having characteristic peaks at 2Theta values corresponding to 9.34.+-.0.1, 10.83.+-.0.1, 19.44.+-.0.1, 20.09.+-.0.1 and 25.41.+-.0.1 degrees. 2. A pharmaceutical composition comprising a compound according to claim 1 and one or more conventional auxiliary substances and/or carriers. 3. A method of treating a patient suffering from a depressive disorder, comprising administering to said patient a compound according to claim 1. 4. A compound which is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride monohydrate in crystalline modification V (Form V) having characteristic peaks at 2Theta values corresponding to 9.34, 10.83, 13.00, 13.47, 18.70, 19.44, 20.09, 20.98, 25.41 and 26.13 degrees. 5. A compound which is 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride monohydrate in crystalline modification V (Form V) having characteristic peaks at 2Theta values corresponding to those exhibited in FIG. 18. 6. A compound which is 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride monohydrate in crystalline modification V (Form V) having an IR spectrum with wavenumbers corresponding to the wavenumbers exhibited in FIG. 6. 7. The compound according to claim 1, wherein the compound has a solubility of about 0.18 .mu.g/mL. 8. The compound according to claim 1, wherein the compound further has at least one characteristic peak at a 2Theta value of corresponding to 13.00 .+-.0.1, 13.47.+-.0.1, 18.70.+-.0.1, 20.98.+-.0.1 and 26.13.+-.0.1. 9. A compound which is 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride monohydrate in crystalline modification V (Form V) having at least five characteristic peaks at 2Theta values selected from 9.34 .+-.0.1, 10.83.+-.0.1, 13.00.+-.0.1, 13.47.+-.0.1, 18.70.+-.0.1, 19.44.+-.0.1, 20.09.+-.0.1, 20.98.+-.0.1, 25.41.+-.0.1 and 26.13.+-.0.1 degrees. 10. The method of claim 3, wherein the depressive disorder is major depressive disorder. 11. A method of treating a patient suffering from major depressive disorder comprising administering to the patient the compound of claim 9.